$9.75
0.040.41%
Pre-Market: 8:01 AM EDT
15 minutes delayed
Comments
Loading...
Kyverna Therapeutics
KYTXNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Kyverna Therapeutics (NASDAQ:KYTX) Stock, Analyst Ratings, Price Targets, Forecasts
Kyverna Therapeutics Inc has a consensus price target of $29 based on the ratings of 3 analysts. The high is $40 issued by Morgan Stanley on March 4, 2024. The low is $8 issued by HC Wainwright & Co. on July 16, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and JP Morgan on July 16, 2024, July 3, 2024, and March 4, 2024, respectively. With an average price target of $18.33 between HC Wainwright & Co., HC Wainwright & Co., and JP Morgan, there's an implied 88.03% upside for Kyverna Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
JP Morgan
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Kyverna Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/16/2024 | Buy Now | -17.95% | HC Wainwright & Co. | Mitchell Kapoor | $8 → $8 | Reiterates | Neutral → Neutral | Get Alert |
| 07/03/2024 | Buy Now | -17.95% | HC Wainwright & Co. | Mitchell Kapoor | → $8 | Initiates | → Neutral | Get Alert |
| 03/04/2024 | Buy Now | 300% | JP Morgan | Brian Cheng | → $39 | Initiates | → Overweight | Get Alert |
| 03/04/2024 | Buy Now | 310.26% | Morgan Stanley | Michael Ulz | → $40 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Kyverna Therapeutics (KYTX) stock?
The latest price target for Kyverna Therapeutics (NASDAQ:KYTX) was reported by HC Wainwright & Co. on July 16, 2024. The analyst firm set a price target for $8.00 expecting KYTX to fall to within 12 months (a possible -17.95% downside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kyverna Therapeutics (KYTX)?
The latest analyst rating for Kyverna Therapeutics (NASDAQ:KYTX) was provided by HC Wainwright & Co., and Kyverna Therapeutics reiterated their neutral rating.
When was the last upgrade for Kyverna Therapeutics (KYTX)?
There is no last upgrade for Kyverna Therapeutics
When was the last downgrade for Kyverna Therapeutics (KYTX)?
There is no last downgrade for Kyverna Therapeutics.
When is the next analyst rating going to be posted or updated for Kyverna Therapeutics (KYTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kyverna Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kyverna Therapeutics was filed on July 16, 2024 so you should expect the next rating to be made available sometime around July 16, 2025.
Is the Analyst Rating Kyverna Therapeutics (KYTX) correct?
While ratings are subjective and will change, the latest Kyverna Therapeutics (KYTX) rating was a reiterated with a price target of $8.00 to $8.00. The current price Kyverna Therapeutics (KYTX) is trading at is $9.75, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.